Breast Nurse Intervention to Improve Adherence to Endocrine Therapy Among Breast Cancer Patients in South Ethiopia.
Ethiopia
adherence
breast cancer
breast nurse
peripheral hospitals
tamoxifen
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 08 2022
05 08 2022
Historique:
received:
11
01
2022
accepted:
09
03
2022
pubmed:
8
5
2022
medline:
10
8
2022
entrez:
7
5
2022
Statut:
ppublish
Résumé
Many women in rural Ethiopia do not receive adjuvant therapy following breast cancer surgery despite the majority being diagnosed with estrogen-receptor-positive breast cancer and tamoxifen being available in the country. We aimed to compare a breast nurse intervention to improve adherence to tamoxifen therapy for breast cancer patients. The 8 hospitals were randomized to intervention and control sites. Between February 2018 and December 2019, patients with breast cancer were recruited after their initial surgery. The primary outcome of the study was adherence to tamoxifen therapy by evaluating 12-month medication-refill data with medication possession ratio (MPR) and using a simplified medication adherence scale (SMAQ) in a subjective assessment. A total of 162 patients were recruited (87 intervention and 75 control). Trained nurses delivered education and provided literacy material, gave additional empathetic counselling, phone call reminders, and monitoring of medication refill at the intervention hospitals. Adherence according to MPR at 12 months was high in both the intervention (90%) and control sites (79.3%) (P = .302). The SMAQ revealed that adherence at intervention sites was 70% compared with 44.8% in the control sites (P = .036) at 12 months. Persistence to therapy was found to be 91.2% in the intervention and 77.8% in the control sites during the one-year period (P = .010). Breast nurses can improve cost-effective endocrine therapy adherence at peripheral hospitals in low-resource settings. We recommend such task sharing to overcome the shortage of oncologists and distances to central cancer centers.
Identifiants
pubmed: 35524760
pii: 6582290
doi: 10.1093/oncolo/oyac081
pmc: PMC9355816
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Tamoxifen
094ZI81Y45
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e650-e660Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Oncology. 2006;71(1-2):1-9
pubmed: 17344666
Lancet. 2017 Feb 25;389(10071):871-880
pubmed: 27814964
Breast Care (Basel). 2021 Oct;16(5):484-490
pubmed: 34720808
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
Breast Cancer Res Treat. 2019 May;175(1):181-189
pubmed: 30706190
Ethiop J Health Sci. 2015 Jan;25(1):53-62
pubmed: 25733785
BMC Cancer. 2014 Nov 29;14:895
pubmed: 25433805
Nat Rev Cancer. 2014 Dec;14(12):815-21
pubmed: 25355378
Breast Cancer Res Treat. 2018 Jul;170(1):111-118
pubmed: 29479644
Oncol Nurs Forum. 2014 Nov 1;41(6):660-8
pubmed: 25355021
Lancet Oncol. 2013 Apr;14(4):e152-7
pubmed: 23561746
Age Ageing. 2017 Sep 1;46(5):747-754
pubmed: 28510645
J Natl Compr Canc Netw. 2021 Dec 29;:1-11
pubmed: 34965508
Breast Cancer Res Treat. 2011 Jan;125(1):191-200
pubmed: 20495864
Lancet Oncol. 2002 Nov;3(11):654
pubmed: 12424066
Oncologist. 2021 Jun;26(6):e1009-e1017
pubmed: 33650727
BMJ Open. 2014 Jun 12;4(6):e005285
pubmed: 24928595
MedGenMed. 2005 Mar 16;7(1):4
pubmed: 16369309
Breast Cancer Res Treat. 2018 Feb;167(3):615-633
pubmed: 29110151
Breast Cancer Res Treat. 2011 Sep;129(2):299-308
pubmed: 21594663
Infect Agent Cancer. 2017 Feb 14;12:13
pubmed: 28228841
World J Surg Oncol. 2015 Jul 19;13:220
pubmed: 26187151
Oncol Nurs Forum. 2016 May 1;43(3):E94-E103
pubmed: 27105205
Am J Cancer Res. 2020 May 01;10(5):1568-1591
pubmed: 32509398
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Cancer Surviv. 2021 Feb;15(1):29-39
pubmed: 32804353
Clin J Oncol Nurs. 2008 Apr;12(2):213-21
pubmed: 18390458
Oncology (Williston Park). 2006 Sep;20(10 Suppl Nurse Ed):50-4; discussion 55
pubmed: 18153980
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Can J Surg. 2014 Feb;57(1):26-32
pubmed: 24461223
Semin Oncol Nurs. 2007 Nov;23(4 Suppl 2):S17-22
pubmed: 18054678
BMC Cancer. 2012 Oct 15;12:474
pubmed: 23066928
Int J Cancer. 2020 Mar 1;146(5):1208-1218
pubmed: 31087650
Lancet Oncol. 2013 Apr;14(4):289-90
pubmed: 23561741
Psychooncology. 2019 Feb;28(2):255-263
pubmed: 30511789
J Adolesc Young Adult Oncol. 2016 Mar;5(1):16-23
pubmed: 26812461
Oncologist. 2015 Jun;20(6):598-604
pubmed: 25933930
Breast Cancer Res Treat. 2012 May;133(1):357-66
pubmed: 22315131
Ethiop J Health Sci. 2017 May;27(3):255-262
pubmed: 29217924
Lancet Oncol. 2021 May;22(5):578-581
pubmed: 33691141
Curr Treat Options Oncol. 2018 Apr 27;19(5):26
pubmed: 29704066
Oncologist. 2016 Jun;21(6):739-44
pubmed: 27091419
Int J Cancer. 2014 Aug 1;135(3):702-9
pubmed: 24375396
Cancer Prev Res (Phila). 2014 Apr;7(4):378-87
pubmed: 24441675
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Obstet Gynecol Int. 2011;2011:143506
pubmed: 21785601
J Cancer Surviv. 2014 Dec;8(4):603-10
pubmed: 24866922
Breast. 2008 Jun;17(3):227-38
pubmed: 18077168
Cancer. 2008 Oct 15;113(8 Suppl):2221-43
pubmed: 18816619
Drugs. 1993 Nov;46(5):819-33
pubmed: 7507033
Lancet Oncol. 2015 Aug;16(8):e405-13
pubmed: 26248848
Clin Trials. 2005;2(2):99-107
pubmed: 16279131
J Clin Oncol. 2008 Feb 1;26(4):556-62
pubmed: 18180462
J Support Oncol. 2007 Mar;5(3):139-43
pubmed: 17410813